The advent of anticancer antibody drugs such as rituximab and trastuzumab has greatly changed the internal medical treatment for malignant tumors, and the development of antibody drugs against various cancer antigens has progressed. However, for an antibody alone to exert sufficient anticancer effects, it is necessary that the target cell membrane molecule is highly expressed in cancer cells, while its expression in normal tissues is extremely low, and target molecules that meet this condition were rare. Therefore, the development of ADCs, immune checkpoint inhibitors, and bispecific antibodies, which have stronger efficacy and different anticancer mechanisms than before, has been carried out, and the practical application of next-generation antibody drugs that can be effective even against cancer antigens with less expression is progressing. On the other hand, although many glycan-related antigens have been reported as cancer antigens so far, there are many problems in terms of specificity and expression levels to target anticancer antibody drugs, and although many clinical trials are being conducted, none have been approved so far.